Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

New and Emerging Abortive Therapies for Migraine


CGRP inhibitors and 5HT-1F agonists are novel mechanisms of action for the abortive treatment of migraine headaches, all three drugs of which were FDA approved less than one year ago. These drugs represent a new mode of attack for abortive migraine treatment, and their place in therapy is important to explore, especially for patients with refractory migraine conditions. This presentation will explore the two CGRP inhibitors, Ubrelvy (ubrogepant) and Nurtec (rimegepant), as well as the one 5HT-1F agonist, Reyvow (lasmiditan). Topics discussed will include mechanisms of action as compared with current standards of therapy, adverse effects, potential dosing and kinetic issues, gaps in knowledge relative to long-term use of these drugs, and where in the treatment algorithm these drugs exist.

Fee

$0.00

CE Hours

0.75

CE Units

0.075

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

Accreditation(s)

Disclosure Policy
The disclosure policies of the SIUE School of Pharmacy Office of Continuing Professional Education requires all persons in a position to control content to disclose any relevant financial relationships with commercial interests. If a conflict is identified, the Office of Professional Continuing Education will initiate a process for resolving the conflict.  The existence of relationships does not necessarily imply bias or lessen the value of the activity.  All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The persons required to disclose conflicts include all course faculty, the SIUE CPE administrator, all activity planners and all reviewers.  The relevant commercial financial relationships or affiliations must have occured over the past 12 months.

 
Accreditation Council for Pharmacy Education
Southern Illinois University Edwardsville School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  
 
 
 
The participant must provide the correct NABP ePID number/DOB combination in their electronic profile. All CPE evaluations must be completed within 60 days of completing the activity. It is the participant's responsibility to check that their credit records are correct within the 60 day period after completion of the activity.   Log in to CPE Monitor at www.mycpemonitor.net to view a list of all ACPE-accredited activities you have taken. Any discrepancies must be resolved with the CPE Provider directly and in a timely manner.
 
 
 

 

Support/Credits

We would like to acknowledge Dr. Chris Herndon, Pharm.D., for his assistance as a mentor of this project.

 

 

 

CGRP inhibitors and 5HT-1F agonists are novel mechanisms of action for the abortive treatment of migraine headaches, all three drugs of which were FDA approved less than one year ago. These drugs represent a new mode of attack for abortive migraine treatment, and their place in therapy is important to explore, especially for patients with refractory migraine conditions. This presentation will explore the two CGRP inhibitors, Ubrelvy (ubrogepant) and Nurtec (rimegepant), as well as the one 5HT-1F agonist, Reyvow (lasmiditan). Topics discussed will include mechanisms of action as compared with current standards of therapy, adverse effects, potential dosing and kinetic issues, gaps in knowledge relative to long-term use of these drugs, cost, and where in the treatment algorithm these drugs exist.

Objectives

  • Compare and contrast the mechanisms of action of the standards of therapy with the novel mechanism drugs discussed in this presentation.
  • Analyze and discuss the data pertaining to the drug trials for the novel mechanism drugs discussed.
  • List pros and cons for the use of the novel mechanism drugs discussed as compared with standards of therapy.

Speaker(s)/Author(s)

Kylee Thole, PharmD Candidate
SIUE School of Pharmacy

Matthew Dunahoo, PharmD Candidate
SIUE School of Pharmacy

Activity Number

0480-0000-20-039-H01-P

Release Date: Oct 14, 2020
Credit Expiration Date: Oct 14, 2021

CE Hours

0.75